Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT

[1]  A. Thiébaut,et al.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.

[2]  J. Cisneros,et al.  Risk Factors for Fluconazole-Resistant Candidemia , 2010, Antimicrobial Agents and Chemotherapy.

[3]  D. Marriott,et al.  Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. , 2010, The Journal of antimicrobial chemotherapy.

[4]  E. Anaissie.  Diagnosis and therapy of fungal infection in patients with leukemia--new drugs and immunotherapy. , 2008, Best practice & research. Clinical haematology.

[5]  K. Matsuo,et al.  Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation , 2008, International journal of hematology.

[6]  F. Aversa,et al.  Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States , 2008, Bone Marrow Transplantation.

[7]  T. Ishida,et al.  Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. , 2007, Transplantation proceedings.

[8]  M. Katashima,et al.  Role of micafungin in the antifungal armamentarium. , 2007, Current medicinal chemistry.

[9]  D. Denning,et al.  Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis , 2006, Journal of Infection.

[10]  A. Takagi,et al.  Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. , 2005, Biological & pharmaceutical bulletin.

[11]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Perfect.  Management of invasive mycoses in hematology patients: current approaches. , 2004, Oncology.

[13]  S. Singhal,et al.  Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients , 2004, Bone Marrow Transplantation.

[14]  T. Walsh.  Echinocandins--an advance in the primary treatment of invasive candidiasis. , 2002, The New England journal of medicine.

[15]  T. Walsh,et al.  Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits , 2002, Antimicrobial Agents and Chemotherapy.

[16]  K. Nishimura,et al.  In vitro Activity of FK463, a Novel Lipopeptide Antifungal Agent, against a Variety of Clinically Important Molds , 2002, Chemotherapy.

[17]  F. Ikeda,et al.  Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. , 2002, The Journal of antibiotics.

[18]  M. Martelli,et al.  Haploidentical stem cell transplantation in leukemia. , 2001, Blood reviews.

[19]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[20]  J. Rex,et al.  Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.

[21]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.

[22]  M. Martelli,et al.  The haploidentical option for high-risk haematological malignancies. , 2008, Blood cells, molecules & diseases.

[23]  M. Asaka,et al.  Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation , 2008, International journal of hematology.

[24]  R. Handgretinger,et al.  The history and future prospective of haplo-identical stem cell transplantation. , 2008, Cytotherapy.

[25]  M. Martelli,et al.  Transplants across human leukocyte antigen barriers. , 2002, Seminars in hematology.

[26]  M. Martelli,et al.  Haploidentical stem cell transplantation for acute leukemia , 2002, International journal of hematology.

[27]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  F. Aversa.  Full haplotype mismatched hematopoietic stem cell transplants. , 2002, Haematologica.

[29]  Juan F. García,et al.  Detection of risk groups in myelodysplastic syndromes. A multicenter study. , 2002, Haematologica.